Last updated: March 6, 2026
What is NDC 24208-0004?
NDC 24208-0004 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for the treatment of spinal muscular atrophy (SMA) in pediatric patients. It is approved in the United States and multiple other markets since May 2019.
Market Overview
Market size and epidemiology
- Target population: SMA type 1, the most severe form, affects approximately 1 in 10,000 live births.
- Estimated patient population: about 400-500 eligible infants annually in the U.S. (Perlin et al., 2022).
- Market growth drivers: Increasing diagnosis rates, expanded approvals for older SMA types, and advocacy for early intervention.
Competitive landscape
| Product |
Approval Year |
Indication |
Price (USD) |
Market Share (2022) |
Notes |
| Zolgensma |
2019 |
SMA in children <2 years |
$2.125M |
~90% |
First gene therapy for SMA |
| Spinraza (nusinersen) |
2016 |
SMA in all age groups |
$750,000/initial dose |
~10% |
Alternative, requires multiple doses |
| Evrysdi (risdiplam) |
2020 |
SMA in children >2 months, adults |
$342,000/year |
Minimal |
Oral administration |
Adoption trends
- High upfront cost has limited payer acceptance initially.
- Value-based agreements and alternative payment models are gradually increasing uptake.
- Expanded labels and early diagnosis protocols are driving demand.
Price Projections
Historical pricing context
- Initial list price: $2.125 million for a single dose.
- Pricing model: One-time administration, justified by curative mechanism.
- Cost considerations: High manufacturing costs for complex gene therapies.
Forecast assumptions
- No significant price reduction expected before 2025.
- Payer negotiations are likely to influence effective pricing.
- Larger patient volume could lead to negotiated discounts.
- Introduction of biosimilars or alternative gene therapies is unlikely within 5 years due to current patent protections and the novelty of gene therapy.
Price trajectory projections (2023–2027)
| Year |
Estimated List Price |
Factors Influencing Price |
Notes |
| 2023 |
$2.125 million |
Stable; limited competition |
Continued high demand |
| 2024 |
$2.125 million |
Market stabilization |
No major biosimilar emergence |
| 2025 |
$2.125 million |
Payer negotiations influence |
Potential modest discounts |
| 2026 |
$2.075 million |
Market dynamics |
Entry of alternative therapies |
| 2027 |
$2.025 million |
Price pressures, inflation |
Potential for further discounts |
Sensitivity analysis
- Payer acceptance: High resistance can decrease net prices up to 15–20%.
- Patient volume increases: Could enable tiered discounts, reducing average effective price.
- Regulatory changes: Approval for broader indications or age groups can diversify revenue streams.
Financial Implications
- Gross revenue potential remains high due to single-dose pricing.
- Cost management and manufacturing efficiencies could influence market entry or pricing strategies.
- Payer negotiations and policy reforms remain the largest uncertainties.
Regulatory and Policy Environment
- CMS's value-based pricing and coverage policies are being tested for high-cost drugs like Zolgensma.
- Legislations favoring value-based contracts could impact pricing models.
- Patent protection extends at least until 2030, limiting biosimilar competition.
Key Takeaways
- Zolgensma remains the dominant therapy for SMA in infants, with a stable list price of around $2.125 million.
- Market growth driven by increasing diagnosis rates and expanded indications.
- Pricing projections indicate stability through 2024, with minor price reductions anticipated from 2025 onward.
- Price negotiations, payer policies, and potential competitive developments will influence long-term pricing and market share.
- The high upfront cost necessitates innovative reimbursement models to maintain market access.
FAQs
1. Will Zolgensma's price decrease significantly in the future?
It is unlikely before 2025 due to lack of alternative therapies and high manufacturing costs. Payer negotiations and market dynamics could result in modest discounts thereafter.
2. How does the reimbursement landscape impact Zolgensma sales?
Payer resistance to high upfront costs prompts the adoption of risk-sharing and outcome-based contracts, which could influence net revenues but sustain market access.
3. Are there upcoming competitors for Zolgensma?
Currently, no direct biosimilars exist due to patent protections. New gene therapies are under development but are not expected to reach the market within the next 3-5 years.
4. How does expanding SMA indications affect Zolgensma's market?
Approval for older or broader patient populations can increase demand but may lead to pricing adjustments based on payer negotiations.
5. What factors could disrupt the current pricing projections?
Regulatory changes, breakthroughs in alternative treatments, or pricing reforms targeting high-cost therapies could alter economic assumptions.
References
[1] Perlin, J. E., et al. (2022). SMA Epidemiology and Treatment Trends. Genetics in Medicine, 24(4), 623-631.
[2] Novartis. (2019). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information. Retrieved from https://www.novartis.com/
[3] IQVIA. (2022). US SMA Market Report.
[4] CMS. (2021). Policy updates on high-cost drug reimbursement models.
[5] FDA. (2019). Zolgensma approval document.
